AR116501A1 - Sistema de suministro de polímero líquido para administración extendida de drogas - Google Patents

Sistema de suministro de polímero líquido para administración extendida de drogas

Info

Publication number
AR116501A1
AR116501A1 ARP190102716A ARP190102716A AR116501A1 AR 116501 A1 AR116501 A1 AR 116501A1 AR P190102716 A ARP190102716 A AR P190102716A AR P190102716 A ARP190102716 A AR P190102716A AR 116501 A1 AR116501 A1 AR 116501A1
Authority
AR
Argentina
Prior art keywords
liquid polymer
delivery system
drug administration
polymer delivery
extended drug
Prior art date
Application number
ARP190102716A
Other languages
English (en)
Inventor
Avinash Nangia
John Charles Middleton
Garret Shane Glover
Hove Amy Haller Van
Original Assignee
Tolmar Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Int Ltd filed Critical Tolmar Int Ltd
Publication of AR116501A1 publication Critical patent/AR116501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

Composiciones farmacéuticas de polímeros líquidos que comprenden un polímero líquido biodegradable, un sistema de solventes biocompatibles y un ingrediente farmacéutico activo (API). Las composiciones son útiles para prolongar una liberación prolongada y a largo plazo del API.
ARP190102716A 2018-09-25 2019-09-24 Sistema de suministro de polímero líquido para administración extendida de drogas AR116501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862736182P 2018-09-25 2018-09-25

Publications (1)

Publication Number Publication Date
AR116501A1 true AR116501A1 (es) 2021-05-12

Family

ID=68393030

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102716A AR116501A1 (es) 2018-09-25 2019-09-24 Sistema de suministro de polímero líquido para administración extendida de drogas

Country Status (8)

Country Link
US (1) US20220040201A1 (es)
EP (1) EP3856142A1 (es)
AR (1) AR116501A1 (es)
AU (1) AU2019348739A1 (es)
CA (1) CA3114061A1 (es)
TW (1) TW202027725A (es)
UY (1) UY38386A (es)
WO (1) WO2020065401A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023005807A2 (pt) * 2020-09-30 2023-05-02 Tolmar International Ltd Sistema de liberação de polímero biodegradável para liberação prolongada de testosterona
EP4221688A1 (en) * 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US20220211660A1 (en) * 2020-10-24 2022-07-07 Mason Cave High viscosity thc product and method of manufacture thereof
US20220125755A1 (en) * 2020-10-24 2022-04-28 Kevin Hazen Cannabis time release apparatus and method of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
AU2002226000A1 (en) * 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
CN101862455A (zh) * 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送***
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
PT2323623T (pt) * 2008-08-12 2016-11-04 Novartis Ag Composições farmacêuticas
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2421509B1 (en) * 2009-04-24 2017-11-22 Iceutica Pty Ltd. Production of encapsulated nanoparticles at high volume fractions
US20140309202A1 (en) * 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
ES2836805T3 (es) 2015-08-03 2021-06-28 Tolmar International Ltd Sistema de administración de polímeros líquidos para la administración extendida de fármacos

Also Published As

Publication number Publication date
TW202027725A (zh) 2020-08-01
UY38386A (es) 2020-04-30
CA3114061A1 (en) 2020-04-02
AU2019348739A1 (en) 2021-04-22
EP3856142A1 (en) 2021-08-04
US20220040201A1 (en) 2022-02-10
WO2020065401A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
CL2019002969A1 (es) Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas.
CY1123474T1 (el) Συσκευες παροχης φαρμακου πολλαπλων μοναδων
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
GEP20217243B (en) Orodispersible dosage unit containing an estetrol component
BR112015019546A2 (pt) implante de distribuição de drogas prolongado
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
BR112014029349A2 (pt) métodos, sistemas e dispositivos para administração de fármacos e oclusão vascular
MX2022010831A (es) Formulaciones inyectables de liberacion extendida que comprenden un agente activo de isoxazolina, metodos y usos de las mismas.
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
GEP20217308B (en) Orodispersible dosage unit containing an estetrol component
PE20160534A1 (es) Sistema de administracion intrauterina
PH12018502615A1 (en) Depot formulations
AR105223A1 (es) Compuestos químicos
ECSP21022120A (es) Administración sostenida de polipéptidos similares a la angiopoyetina 3
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
MX2019001884A (es) Entrega local sostenida de farmacos que incluyen antibioticos.
UY38593A (es) Formulaciones farmacéuticas que contienen peg, un ingrediente activo y un inhibidor de cristalización
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
AR096223A1 (es) Pastilla de nicotina para administración oral
MX2022005321A (es) Dispositivos medicos anticonceptivos.
CO2019011299A2 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4
EA201991594A1 (ru) Депо-препарат
UY38900A (es) Composiciones de polímeros líquidos y sistemas de administración prolongada de péptidos como principios activos farmacéuticos